Type 1 Diabetes Today: From Diagnosis to Daily Life – Current Answers from Leading Experts

Introduction

In recent years, our understanding of type 1 diabetes has rapidly evolved—not only in clinical care but also in medical technology and fundamental research. This overview is based entirely on one of the most recent and authoritative scientific articles on the subject: “New advances in type 1 diabetes”, published in 2024 in the British Medical Journal (BMJ). The article was authored by Dr. Savitha Subramanian, Dr. Farah Khan, and Dr. Irl B. Hirsch—experienced researchers and clinicians at the University of Washington Diabetes Institute, with extensive expertise in metabolism, endocrinology, and diabetes care.

This article is designed to provide patients and their families with clear, up-to-date, and practical answers to the most pressing questions that arise after a diagnosis of type 1 diabetes. All information is grounded in evidence-based insights from this landmark BMJ publication.

AUDIO:

What the Experts Say

Below are expert medical opinions and research-backed answers to essential questions about type 1 diabetes, based entirely on the 2024 BMJ publication. Each section begins with a guiding question to help readers easily navigate the topic.

1. What Is Type 1 Diabetes and Why Is Lifelong Insulin Therapy Necessary?

“Type 1 diabetes is an autoimmune condition characterized by the destruction of insulin-producing β-cells in the pancreas, typically leading to severe endogenous insulin deficiency. Without treatment, diabetic ketoacidosis (DKA) develops and death follows; lifelong insulin therapy is therefore essential for survival.”

What This Means: Type 1 diabetes is not caused by lifestyle or diet, but by the immune system mistakenly attacking the cells that produce insulin. Insulin therapy is not optional—it is a life-saving necessity that replaces the hormone your body can no longer produce.

2. What Are the New Technologies for Glucose Monitoring and Why Do They Matter?

“In many parts of the world, home blood glucose monitoring (BGM) has been replaced by continuous glucose monitoring (CGM)—a dynamic view of glycemia. CGM leads to better glucose control… and significantly reduces HbA1c levels compared with BGM. It is a key component in automated insulin delivery systems.”

What This Means: CGM devices give patients and caregivers a more complete and real-time picture of blood sugar levels. This not only improves daily management but has been shown to reduce complications like hypoglycemia and long-term damage. These tools are becoming an essential part of modern diabetes care.

3. How Are New Insulin Types Improving Treatment?

“Insulin degludec was developed to provide longer action and a flatter profile compared to earlier long-acting insulin analogs… Its profile is typically stable without significant day-to-day variability, resulting in fewer hypoglycemic events.”

What This Means: New insulins offer smoother, more predictable effects, allowing for better blood sugar control and a lower risk of dangerous lows, especially overnight. These options are especially valuable for those struggling with frequent hypoglycemia.

4. Are There Additional Medications That Can Help, and When Are They Appropriate?

“GLP-1 receptor agonists may help with weight loss and reducing insulin doses in select patients with type 1 diabetes, but they are not recommended as standard treatment… SGLT-2 inhibitors are effective, but the risk of diabetic ketoacidosis remains a serious limitation.”

What This Means: Some newer drugs, often used in type 2 diabetes, are being explored in type 1. While they can help with weight control or insulin sensitivity, they carry significant risks and should only be used under close medical supervision.

5. How Can I Recognize and Prevent Diabetic Ketoacidosis (DKA)?

“DKA is a serious and potentially fatal hyperglycemic emergency, associated with significant mortality and morbidity… Common triggers include new-onset type 1 diabetes, infections, poor treatment adherence, and acute cardiovascular events.”

What This Means: DKA is a dangerous complication that can occur if insulin levels drop too low. Symptoms include nausea, abdominal pain, rapid breathing, and confusion. It’s critical to act fast and seek emergency care if DKA is suspected.

Frequently Asked Questions (FAQs)

If you or someone you love has been diagnosed with type 1 diabetes, your main concerns are likely about how this disease will affect daily life, what treatment options are available, and what to expect in the future. Here are five key questions with accurate, science-backed answers based on the BMJ article.

1. Can Type 1 Diabetes Develop in Adults—and How Can It Be Recognized?

Answer: Yes. Nearly half of all new type 1 diabetes cases are now diagnosed in adults. Unfortunately, it is often misdiagnosed as type 2 diabetes—this happens in about 40% of cases. In adults, symptoms may be less dramatic than in children, and insulin deficiency may progress more slowly. Diagnosis usually involves testing for autoantibodies (GADA, IA2, ZnT8) and evaluating glucose tolerance. A combination of these helps determine the stage and risk of the disease.

2. What Challenges Will I—and My Family—Face Living with Type 1 Diabetes?

Answer: Living with type 1 diabetes is demanding. It involves constant insulin dosing adjustments, counting carbohydrates (often with uncertain nutritional content), and managing physical activity. Beyond medical care, the emotional and financial burden can be overwhelming. Stress, fear of complications, and “diabetes burnout” are common. Family support and mental health care are essential components of long-term management.

3. What Is “Double Diabetes,” and Should I Worry About My Weight?

Answer: In recent years, obesity rates have increased among people with type 1 diabetes, especially in high-income countries. When type 1 diabetes (an autoimmune insulin deficiency) coexists with insulin resistance (often due to excess weight), the condition is sometimes referred to as “double diabetes” or “hybrid diabetes.” While not officially classified, this combination complicates treatment and makes weight management more difficult. Research is ongoing into the best strategies for this growing group of patients.

4. Can Everyone Benefit from CGMs and Insulin Pumps?

Answer: While CGMs and insulin pumps offer major benefits—including improved blood sugar control and convenience—they're not right for everyone. Some people find the devices intrusive or difficult to use, while others face cost barriers. At a minimum, patients should monitor blood sugar before meals and bedtime using a home glucose meter. Diabetes care should always be tailored to each person’s lifestyle, needs, and preferences.

5. Are There New Treatments That Can Prevent or Delay Type 1 Diabetes?

Answer: Yes. The first FDA-approved immunotherapy that can delay the onset of type 1 diabetes in at-risk individuals is teplizumab, a monoclonal antibody. A single treatment course in people with positive autoantibodies and abnormal glucose tolerance delayed the clinical onset of diabetes by about two years compared to placebo. While not a cure, this is a groundbreaking step forward in prevention.

Conclusion

Type 1 diabetes remains a serious and complex condition, requiring ongoing attention from patients, families, and healthcare providers. But thanks to advances in research, diagnostics, treatment, and technology, we now have better tools than ever before for managing the disease.

As highlighted by Subramanian, Khan, and Hirsch in their 2024 BMJ article, innovations like immunomodulatory therapies, continuous glucose monitoring, and automated insulin delivery systems are transforming diabetes care—and offering real hope for improved quality of life.

Still, the most powerful tools remain: informed patients, proactive families, and timely guidance from qualified medical professionals.

Source: Savitha Subramanian, Farah Khan, Irl B Hirsch. New advances in type 1 diabetes. BMJ 2024;384:e075681. University of Washington Diabetes Institute, Division of Metabolism, Endocrinology and Nutrition, University of Washington, Seattle, WA, USA. DOI: 10.1136/bmj-2023-075681